Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City Capital’s David Beier to outline for policymakers the best approach for tackling the affordability of prescription drugs. “As policy professionals from different sides of the aisle, we believe there is a right way…

During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks Radio, for a discussion about innovation taking place in the biopharma industry, the cost and value of prescription medicines and how the recent midterm elections may impact the drug pricing debate…

The numbers are staggering. The opioid epidemic is costing our nation more than $500 billion annually in health and social costs. What’s more, 1 in 5 deaths among young adults in 2016 were opioid related. This crisis is plaguing communities across the country, leaving in its wake countless victims,…

BIO President and CEO Jim Greenwood posted the following op-ed on Linked-In today, making the case for the U.S. Senate to act on legislation that would empower the Centers for Medicaid and Medicare Services to broaden coverage of medication-assisted treatment to help Americans in the throes of…

BIO and BIO’s Board-level Workforce Development, Diversity and Inclusion (WDDI) Committee were disappointed that the planners of this year’s “Party at BIO - Not Associated with BIO” (PABNAB) included inappropriate entertainment. That decision does not reflect the values of this industry, BIO or the…

One and a half million and counting. That’s how many people suffer from lupus in the United States – and also the number of Americans waiting and praying for the biopharmaceutical industry to find better treatments for this devastating, chronic condition. Lupus is a misunderstood autoimmune…

Part 1. Restricting access under Medicare Part D  The Trump administration is out with its plan to lower the cost of prescription drug for America’s patients. The plan rightly rejects the flawed schemes we hear regularly from pundits and the media — importation and direct government price…

A series of recent studies examining diversity and financial performance have fueled a growing insistence among big-name private equity firms, pension funds and money managers that their investees hire and promote more diverse talent up the ranks – or risk losing their clients’ capital. BIO…

Two-hundred biotech allies from more than 40 different states visited Washington D.C. this week. These advocates met with policymakers on Capitol Hill and in the administration to share BIO’s vision and policy priorities for a strong biotech industry. When it came to the topic of prescription drug…